n CME : Your SA Journal of CPD - Management of dyslipidaemia : main topic
|Article Title||Management of dyslipidaemia : main topic|
|© Publisher:||Health and Medical Publishing Group (HMPG)|
|Journal||CME : Your SA Journal of CPD|
|Publication Date||Jul 2003|
|Pages||378 - 382|
|Keyword(s)||Drug combinations, Drug therapy, Dyslipidaemia, Lifestyle modification and Practical management|
Dyslipidaemia, particularly an elevated LDL-cholesterol level, is the major risk factor for cardiovascular disease. <br>Lifestyle modification is essential and must be applied to all patients with dyslipidaemia. <br>Patients with genetic dyslipidaemia, established cardiovascular disease, diabetes, and those at high cardiovascular risk warrant lipid-modifying drug therapy. <br>Appropriately prescribed lipid-modifying drug therapy can lower cardiovascular morbidity and mortality and improve overall survival. <br>Statins are the most effective agents for the treatment of predominant hypercholesterolaemia. <br>Fibrates are more effective for the treatment of hypertriglyceridaemia. <br>Combination therapy may be required for the treatment of severe dyslipidaemia but side-effects are more likely and costs become substantial.
Article metrics loading...